☰

Phonphimon Wongthida, Ph.D. - Publications

Affiliations: 
2010 Virology and Gene Therapy College of Medicine - Mayo Clinic 
Area:
Virology Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Kottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, Huff AL, Zell B, Thompson JM, Wongthida P, Pulido J, Schuelke MR, Samson A, Selby P, Ilett E, et al. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications. 12: 1930. PMID 33772027 DOI: 10.1038/s41467-021-22115-1  0.676
2020 Huff AL, Evgin L, Thompson J, Kottke T, Driscoll CB, Tonne J, Wongthida P, Schuelke M, Shim KG, Mer G, Ramirez-Alvarado M, Vile R. Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32877695 DOI: 10.1016/J.Ymthe.2020.08.013  0.724
2020 Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11: 3187. PMID 32581235 DOI: 10.1038/S41467-020-17011-Z  0.826
2020 Wongthida P, Schuelke MR, Driscoll CB, Kottke T, Thompson JM, Tonne J, Stone C, Huff AL, Wetmore C, Davies JA, Parker AL, Evgin L, Vile RG. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology. PMID 32459315 DOI: 10.1093/Neuonc/Noaa126  0.695
2020 Driscoll CB, Schuelke MR, Kottke T, Thompson JM, Wongthida P, Tonne JM, Huff AL, Miller A, Shim KG, Molan A, Wetmore C, Selby P, Samson A, Harrington K, Pandha H, et al. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11: 790. PMID 32034147 DOI: 10.1038/S41467-020-14568-7  0.726
2019 Schuelke MR, Wongthida P, Thompson J, Kottke T, Driscoll CB, Huff AL, Shim KG, Coffey M, Pulido J, Evgin L, Vile RG. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal For Immunotherapy of Cancer. 7: 188. PMID 31315671 DOI: 10.1186/S40425-019-0673-2  0.641
2019 Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Kaluza Smith K, Harris RS, Coffey M, Pulido JS, Pandha H, et al. Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from Frontline Treatment. Cancer Immunology Research. PMID 30940643 DOI: 10.1158/2326-6066.Cir-18-0013  0.776
2019 Vile R, Evgin L, Kottke T, Schuelke M, Driscoll CB, Huff AL, Thompson J, Molan A, Harris RS, Pulido JS, Wongthida P. Abstract B138: Cancer immunotherapy with APOBEC3B-induced heteroclitic library tumor cell vaccines and immune checkpoint blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B138  0.69
2019 Huff AL, Wongthida P, Kottke T, Thompson J, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile R. Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A133  0.65
2019 Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Sampson J, Perez LS, Vile R. Abstract A029: Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T-cells Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A029  0.739
2018 Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG. APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy Oncolytics. 11: 1-13. PMID 30294666 DOI: 10.1016/J.Omto.2018.08.003  0.651
2018 Uusi-Kerttula H, Davies JA, Thompson J, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile R, Chester JD, Parker AL. Ad5-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29798908 DOI: 10.1158/1078-0432.Ccr-18-1089  0.53
2018 Schuelke M, Evgin L, Wongthida P, Thompson J, Kottke T, Sanchez-Perez L, Sampson J, Vile R. IMMU-12. T-CELL THERAPIES DEMONSTRATE EFFICACY WITHOUT TOXICITY IN IMMUNOCOMPETENT MODELS OF BRAINSTEM TUMORS Neuro-Oncology. 20: i101-i101. DOI: 10.1093/Neuonc/Noy059.328  0.728
2017 Wongthida P, Liwnaree B, Wanasen N, Narkpuk J, Jongkaewwattana A. The role of ORF3 accessory protein in replication of cell-adapted porcine epidemic diarrhea virus (PEDV). Archives of Virology. PMID 28474223 DOI: 10.1007/S00705-017-3390-5  0.458
2016 Wanitchang A, Wongthida P, Jongkaewwattana A. Influenza B virus M2 protein can functionally replace its influenza A virus counterpart in promoting virus replication. Virology. 498: 99-108. PMID 27567258 DOI: 10.1016/J.Virol.2016.08.016  0.377
2016 Wongthida P, Jengarn J, Narkpuk J, Koonyosying P, Srisutthisamphan K, Wanitchang A, Leaungwutiwong P, Teeravechyan S, Jongkaewwattana A. In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion. Plos One. 11: e0157287. PMID 27315286 DOI: 10.1371/Journal.Pone.0157287  0.477
2016 Teeravechyan S, Frantz PN, Wongthida P, Chailangkarn T, Jaru-Ampornpan P, Koonpaew S, Jongkaewwattana A. Deciphering the biology of porcine epidemic diarrhea virus in the era of reverse genetics. Virus Research. PMID 27212685 DOI: 10.1016/J.Virusres.2016.05.003  0.371
2015 Narkpuk J, Jaru-Ampornpan P, Subali T, Bertulfo FC, Wongthida P, Jongkaewwattana A. Mechanistic study of intertypic nucleoprotein complex formation and its inhibitory effect toward influenza A virus. Virology. 485: 104-15. PMID 26218215 DOI: 10.1016/J.Virol.2015.06.032  0.337
2015 Jengarn J, Wongthida P, Wanasen N, Frantz PN, Wanitchang A, Jongkaewwattana A. Genetic manipulation of porcine epidemic diarrhoea virus recovered from a full-length infectious cDNA clone. The Journal of General Virology. 96: 2206-18. PMID 25979733 DOI: 10.1099/Vir.0.000184  0.396
2012 Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Research. 72: 4753-64. PMID 22836753 DOI: 10.1158/0008-5472.Can-12-0600  0.797
2012 Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology. 30: 337-43. PMID 22426030 DOI: 10.1038/Nbt.2157  0.724
2012 Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Erratum: Corrigendum: Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors Nature Medicine. 18: 1445-1445. DOI: 10.1038/Nm0912-1445D  0.572
2011 Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine. 17: 854-9. PMID 21685898 DOI: 10.1038/Nm.2390  0.728
2011 Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Human Gene Therapy. 22: 1343-53. PMID 21366404 DOI: 10.1089/Hum.2010.216  0.807
2011 Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 140-9. PMID 20978474 DOI: 10.1038/Mt.2010.224  0.759
2011 Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 150-8. PMID 20959810 DOI: 10.1038/Mt.2010.225  0.72
2010 Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Research. 70: 4539-49. PMID 20484025 DOI: 10.1158/0008-5472.Can-09-4658  0.709
2010 Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Therapy. 17: 158-70. PMID 20016540 DOI: 10.1038/Gt.2009.161  0.743
2010 Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Human Gene Therapy. 21: 439-50. PMID 19922169 DOI: 10.1089/Hum.2009.143  0.791
2009 Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Research. 69: 7713-20. PMID 19773437 DOI: 10.1158/0008-5472.Can-09-1013  0.677
2008 Kottke T, Galivo F, Wongthida P, Maria Diaz R, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1217-1226. PMID 28178481 DOI: 10.1038/Mt.2008.83  0.728
2008 Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1910-8. PMID 18827807 DOI: 10.1038/Mt.2008.212  0.799
2008 Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1217-26. PMID 18431359 DOI: 10.1038/mt.2008.83  0.701
2008 Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Medicine. 14: 37-44. PMID 18066076 DOI: 10.1038/Nm1681  0.692
2007 Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Research. 67: 2840-8. PMID 17363607 DOI: 10.1158/0008-5472.Can-06-3974  0.799
Show low-probability matches.